AUTL news

Latest 2 stories · newest Aug 3, 2026

AUTL

Autolus Preliminary Q2 2026 Net Product Revenue $45M

Autolus reports preliminary Q2 2026 net product revenue of approximately $45 million and increased FY 2026 sales guidance to $140–$150 million. The company also announced a strategic financing agreement with Perceptive Advisors for up to a $250 million credit facility.

Offering|Guidance Aug 3, 2026 sentiment +0.30 SEC filing ↗

AUTL

Autolus Therapeutics releases 2025 annual report and financial statements

Autolus Therapeutics plc, a Nasdaq-listed biopharmaceutical company, published its annual report and consolidated financial statements for the year ended December 31, 2025. The filing provides comprehensive financial performance data and corporate governance information for the cell therapy develope…

Other Jun 9, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AUTL feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AUTL/newsSTART FREE